Heart attack diagnostics market sales create significant incremental opportunity over 2032

In the test sector, blood tests from the heart attack diagnostics market are anticipated to flourish at the quickest CAGR of 6.8% through 2032

0
42
New Delhi: According to a recent report by Fact.MR, a market research and competitive intelligence provider, demand for the heart attack diagnostics market is estimated to grow at a 7.1% CAGR, from US$ 11.2 Billion by 2022 to US$ 22.2 Billion by 2032.
The COVID-19 pandemic has substantially influenced the market for heart attack diagnoses. People with heart disorders are more likely to develop the virus, especially those prone to heart attacks, and there is a substantial risk of mortality if the infection is not detected in time. Furthermore, several of the early symptoms of COVID-19 are similar to heart attacks, such as chest discomfort, nausea, exhaustion, and difficulty breathing.
The rise in cases of coronary heart disease, technological advancements in ECG devices such as handheld and portable, an increase in geriatric populations, rising obesity and tobacco smoking, a shift toward an unhealthy lifestyle, and favorable government regulations regarding monitoring devices are all factors driving the growth of the heart attack diagnostics market.
Furthermore, an increase in healthcare expenditure, collaborations and partnerships between key players to facilitate drug development; an increase in R&D activities; the launch of novel devices; and technological development are factors driving the growth of the heart attack diagnostics market.
However, the greater cost of diagnostic instruments, a shortage of experienced professionals, and the low Medicare reimbursement granted for mobile cardiac outpatient telemetry electrocardiogram (ECG) would impede the growth of the heart attack diagnostics market.
The increasing prevalence of cardiovascular illnesses, the ageing of the population, and the rising need for advanced cardiovascular therapy would drive the expansion of the heart attack diagnostics market.
Furthermore, growing healthcare spending, collaborations and partnerships among major players, increased R & D, launches of innovative created devices and technical improvements are some of the factors driving the growth of the heart attack diagnostics market.
Key Takeaways:
  • In the test sector, blood tests from the heart attack diagnostics market are anticipated to flourish at the quickest CAGR of 6.8% through 2032.
  • With a CAGR of 6.7% through 2032, Hospitals are predicted to grow significantly in the end-use sector of the heart attack diagnostics market.
  • The market size for heart attack diagnostics market in the United States is expected to reach US$ 7.7 Billion by 2032, growing at a CAGR of 6.8% during the forecast period.
  • United Kingdom is anticipated to reach a market size of US$ 926.5 Million in Heart attack diagnostics by 2032, with a CAGR of 6.1% during the forecast period.
  • China’s Heart attack diagnostics market is anticipated to be worth US$ 1.6 million by 2032, with a CAGR of 6.4% over the forecast period.
  • Japan is expected to have a market size for Heart attack diagnostics of US$ 1.3 Billion by 2032, with a CAGR of 5.4% during the forecast period.
  • By 2032, South Korea is expected to reach a market size of US$ 839.6 Million in heart attack diagnostics, with a CAGR of 5% during the forecast period.
Competitive Landscape:
The heart attack diagnostics market is projected to be extremely competitive, with numerous prominent competitors. New quick and portable (flexible) blood and enzyme-based diagnostics have the potential to dominate the heart attack diagnostics market and drive innovation in these areas.
Advancements in ECG technology may be game changers for low-income nations and severe heart-related disorders. Siemens Healthcare GmbH, Schiller AG, GE Healthcare, Hitachi Medical Systems, and F Hoffmann-La Roche Ltd are among the prominent companies.

These insights are based on a report on Heart Attack Diagnostics Market by Fact.MR.